From US tariff opportunities to the risk of a magnitude 8 earthquake in China, here are five stories you may have missed over ...

The problems could cost the equivalent of US$57 billion, around 22 per cent of the total national health budget.

(Reuters) -Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United Laboratories International's weight-loss drug candidate in a deal worth up to ...

Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G" weight-loss drug candidate in a deal worth up to $2 billion.

China is encouraging qualified hospitals nationwide to establish weight management clinics to achieve near-complete ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. China’s obesity crisis is a sizeable profit opportunity. More than half of Chinese adults are overweight ...

Beijing (AsiaNews/Agencies) – China is stepping up efforts to counter the rise in obesity, placing scales in hotel rooms and promoting healthy recipes on social media. The initiative ...

Obesity in girls rose to 7.7% in 2022 from 0.6% in 1990. “Obesity has become a major public health issue in China, ranking as the sixth leading risk factor for death and disability in the ...

The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.